Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

Core Insights - Clearside Biomedical, Inc. has received approval from Health Canada for XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use in treating uveitic macular edema (UME) [1] - XIPERE is now approved in multiple markets including the United States, Canada, Australia, and Singapore, with ongoing regulatory review in China [2] Product Overview - XIPERE is a proprietary corticosteroid suspension designed for administration to the suprachoroidal space, specifically targeting macular edema associated with uveitis [3] - The product is commercially available in the U.S. and is exclusively licensed for commercialization and development in the U.S. and Canada to Bausch + Lomb, while Arctic Vision holds the license for Greater China and other regions [3] Technology and Platform - Clearside's suprachoroidal space (SCS®) injection platform provides innovative access to the back of the eye, enhancing the delivery of therapies and potentially improving treatment efficacy [4] - The SCS Microinjector® is designed to deliver various drug candidates into the suprachoroidal space, aiming to minimize toxic effects on non-diseased cells [4] Company Background - Clearside Biomedical focuses on revolutionizing therapy delivery to the back of the eye, with a pipeline that includes small molecule product candidates for administration via the SCS Microinjector [5] - The company's lead program, CLS-AX (axitinib injectable suspension), is prepared for Phase 3 trials targeting neovascular age-related macular degeneration (wet AMD) [5]